This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cinven Buys Medpace In $915M Deal

LONDON (The Deal) -- Buyout firm Cinven Ltd. said Monday it would buy a majority stake in medical contract research company Medpace in a deal which values the business at $915 million including debt and provides an exit for CCMP Capital Advisors LLC.

Cinven prevailed in an auction, beating late-stage bidders including GTCR LLC and Summit Partners with a deal to buy a roughly 80% stake. Medpace, of Cincinnati, generated adjusted Ebitda of $94 million in 2013 and was founded in 1992 by August Troendle, who is president and CEO, and who, with other managers, will hold the remaining shares.

Cinven said it expects strong growth in the contract research industry as clinical trials become more complex. It noted that the outlook for research and development expenditure is most positive for the smaller pharma and biotech companies which Medpace serves. Cinven said it wants to expand Medpace in its own geographical sweetspots of Europe and Asia and increase Medpace's business in newer sectors, including the metabolic, cardiovascular and central nervous system therapeutic areas.

"Cinven's healthcare team identified the CRO [contract research organization] industry as an attractive market in which to invest given its fundamental growth characteristics. The CRO industry consolidation has created a gap in the market serving the mid-cap pharma and smaller biotech players - where Medpace operates and where we intend to capitalize on organic growth opportunities," said Cinven partner Supraj Rajagopalan in a statement.

The buyout firm is financing the purchase with equity from its fifth, 5.3 billion euros ($7.3 billion) fund, which it closed last year, as well as with committed first-lien, U.S. dollar-denominated debt within a covenant-lite structure. The financing package is known to amount to about 55% of Medpace's $915 million enterprise value.

Cinven said it plans to replicate the types of expansion strategies it employed for Swedish diagnostics company Phadia AB, which it sold to Thermo Fisher Scientific Inc. in 2011 for 2.47 billion euros, or a money multiple of 3.2 times, having transformed its small U.S. business to Phadia's largest and fastest-growing geographical market; and for current portfolio company Sebia SA. Cinven bought the French diagnostics company from Montagu Private Equity LLP for 800 million euros in 2010 and has since expanded it in the U.S. and Asia.

Cinven doesn't envision striking transformative M&A transactions for Medpace but would consider bolt-on purchases for the Ohio business in Europe and Asia, a source said.

New York private equity firm CCMP agreed to buy Medpace in May 2011 in a deal known to have been worth about $535 million. A source said the buyout firm made 3 times its money and a 48% internal rate of return on the investment.

CCMP's Ryan Anderson and Kevin O'Brien, as well as CCMP president and CEO Stephen Murray, oversaw the process for the New York buyout firm, alongside Medpace's Troendle and CFO Jesse Geiger. As well as Rajagopalan, Cinven principal Alex Leslie also oversaw the purchase for the buyout firm.

A Barclays plc team led by Elizabeth Mily and a Wells Fargo Securities LLC team of Omid Ahdieh, Andrew Halverstam and David Cannon advised Cinven, while Medpace and CCMP were advised by Jefferies LLC's Michael Gerardi, Matthew Miller, Michael Leder, Jeffrey Greenip, James Seagrave and a Fairmount Partners LP team led by Neal McCarthy. Fairmount Partners advised on the 2011 sale of Medpace to CCMP and on Medpace's 2012 purchase of devices contract research organization Meditech Holding BV, of the Netherlands. A Weil, Gotshal & Manges LLP team including Harvey Eisenberg and Matthew Brush provided Medpace's legal advice.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs